Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Therapeutic drug monitoring of indinavir and nelfinavir to assess adherence to therapy in human immunodeficiency virus-infected children.

van Rossum AM, Bergshoeff AS, Fraaij PL, Hugen PW, Hartwig NG, Geelen SP, Wolfs TF, Weemaes CM, De Groot R, Burger DM.

Pediatr Infect Dis J. 2002 Aug;21(8):743-7.

PMID:
12192162
2.

Nelfinavir mesylate.

Tebas P, Powderly WG.

Expert Opin Pharmacother. 2000 Dec;1(7):1429-40. Review.

PMID:
11249476
3.

Resolution of HIV-associated nephrotic syndrome with highly active antiretroviral therapy delivered by gastrostomy tube.

Viani RM, Dankner WM, Muelenaer PA, Spector SA.

Pediatrics. 1999 Dec;104(6):1394-6. Review.

PMID:
10585995
4.

Principles and practice of HIV-protease inhibitor pharmacoenhancement.

Moyle GJ, Back D.

HIV Med. 2001 Apr;2(2):105-13. Review.

5.

The role of protease inhibitor therapy in children with HIV infection.

Gavin PJ, Yogev R.

Paediatr Drugs. 2002;4(9):581-607. Review.

PMID:
12175273
6.

Nelfinavir, a new protease inhibitor: early clinical results.

Powderly WG, Tebas P.

AIDS. 1999 Sep;13 Suppl 1:S41-8. Review.

PMID:
10546784
7.

Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection.

Grub S, Delora P, L├╝din E, Duff F, Fletcher CV, Brundage RC, Kline MW, Calles NR, Schwarzwald H, Jorga K.

Clin Pharmacol Ther. 2002 Mar;71(3):122-30. Review.

PMID:
11907486
8.

Nelfinavir: an update on its use in HIV infection.

Bardsley-Elliot A, Plosker GL.

Drugs. 2000 Mar;59(3):581-620. Review.

PMID:
10776836
10.

Efficacy of highly active antiretroviral therapy in HIV-1 infected children.

van Rossum AM, Fraaij PL, de Groot R.

Lancet Infect Dis. 2002 Feb;2(2):93-102. Review.

PMID:
11901656
11.

Boosted protease inhibitors as a therapeutic option in the treatment of HIV-infected children.

Ramos J.

HIV Med. 2009 Oct;10(9):536-47. doi: 10.1111/j.1468-1293.2009.00728.x. Review.

12.

Anti-retroviral therapy for HIV-infected children--toward maximal effectiveness.

Melvin AJ.

Pediatr Infect Dis J. 1999 Aug;18(8):723-4. Review.

PMID:
10462343
13.

Summary of track B: clinical science.

De Cock KM, Churchill D, Grant A, Del Amo J, Rouleau D, Zala C, Harris M, Pozniak A, Williams I.

AIDS. 1996 Dec;10 Suppl 3:S107-13. Review.

PMID:
8970717
14.

Evaluation of simplified protease inhibitor dosing regimens for the treatment of HIV infection.

Cohen CJ, Hellinger J, Norris D.

AIDS Read. 2000 May;10(5):296-9, 304-7, 311-3. Review.

PMID:
10851721
15.

Adherence to antiretroviral therapy by human immunodeficiency virus-infected patients.

Turner BJ.

J Infect Dis. 2002 May 15;185 Suppl 2:S143-51. Review.

PMID:
12001036
16.

Antiretroviral therapy response among HIV-2 infected patients: a systematic review.

Ekouevi DK, Tchounga BK, Coffie PA, Tegbe J, Anderson AM, Gottlieb GS, Vitoria M, Dabis F, Eholie SP.

BMC Infect Dis. 2014 Aug 26;14:461. doi: 10.1186/1471-2334-14-461. Review.

17.

Levels of adherence required for virologic suppression among newer antiretroviral medications.

Kobin AB, Sheth NU.

Ann Pharmacother. 2011 Mar;45(3):372-9. doi: 10.1345/aph.1P587. Epub 2011 Mar 8. Review.

PMID:
21386024
18.

Drug interactions between HIV protease inhibitors and acid-reducing agents.

Falcon RW, Kakuda TN.

Clin Pharmacokinet. 2008;47(2):75-89. Review.

PMID:
18193914
19.

Nelfinavir mesylate: a protease inhibitor.

Pai VB, Nahata MC.

Ann Pharmacother. 1999 Mar;33(3):325-39. Review.

PMID:
10200859
20.

Factors affecting adherence to antiretroviral therapy.

Chesney MA.

Clin Infect Dis. 2000 Jun;30 Suppl 2:S171-6. Review.

PMID:
10860902

Supplemental Content

Support Center